Evaluation of zinc (II) chelators for inhibiting p53-mediated apoptosis

Akinori Morita1, Shinya Ariyasu, Soichiro Ohya

  • 1Department of Radiological Science, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan.

Oncotarget
|November 28, 2013
PubMed

Insights

Sodium orthovanadate and zinc chelators like Bispicen protect against radiation by inhibiting p53 apoptosis. These compounds induce p53 denaturation, blocking key cell death pathways for radioprotection.

Area of Science:

  • Radiation biology
  • Molecular oncology
  • Biochemistry

Background:

  • Sodium orthovanadate (vanadate) previously showed radioprotective effects by inhibiting p53 apoptotic pathways.
  • Vanadate uniquely induces p53 denaturation compared to other inhibitors like pifithrin-α and pifithrin-µ.
  • This study sought new p53 inhibitors that induce p53 denaturation for radioprotection.

Purpose of the Study:

  • To identify novel inhibitors of radiation-induced apoptosis.
  • To investigate zinc (II) chelators as potential p53 denaturation agents.
  • To explore new strategies for radioprotection.

Main Methods:

  • Screened zinc (II) chelators for inhibiting p53 DNA binding in vitro.
  • Tested apoptosis suppression in MOLT-4 cells exposed to radiation.
  • Conducted mechanistic studies using cells with varying p53 status and p53-independent stimuli.

Main Results:

  • Two of five zinc (II) chelators suppressed radiation-induced apoptosis.
  • Bispicen exhibited the highest inhibitory activity.
  • Bispicen, like vanadate, induced p53 denaturation and blocked both transcription-dependent and -independent apoptotic pathways, acting specifically through p53.

Conclusions:

  • Zinc (II) chelators represent a novel approach for radioprotection.
  • Inhibiting p53-dependent apoptosis via p53 denaturation is a viable strategy.
  • Bispicen shows promise as a radioprotective agent by targeting p53 denaturation.